Ftse Mib
33.330,25
-0,63%
DAX
18.236,43
0,40%
S&P 500
5.479,02
0,02%
NASDAQ
17.849,16
0,25%
Bitcoin
61.677,13
1,42%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Cyclo Therapeutics Inc (CYTH) Cyclo Therapeutics Inc (CYTH) Notizie

CYTH

Cyclo Therapeutics (CYTH)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYTH
DataOraFonteTitoloSimboloCompagnia
25/06/202415:25Business WireCyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024NASDAQ:CYTHCyclo Therapeutics Inc
14/06/202422:01GlobeNewswire Inc.Rafael Holdings Reports Third Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
30/05/202415:00Business WireCyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1NASDAQ:CYTHCyclo Therapeutics Inc
16/05/202414:05Business WireCyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
18/03/202414:05Business WireCyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYTHCyclo Therapeutics Inc
14/03/202414:34Business WireCyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s DiseaseNASDAQ:CYTHCyclo Therapeutics Inc
13/03/202422:04GlobeNewswire Inc.Rafael Holdings Reports Second Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
04/03/202422:33Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
15/02/202422:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
14/02/202420:44Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
29/01/202415:15Business WireCyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark OfficeNASDAQ:CYTHCyclo Therapeutics Inc
22/01/202412:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTHCyclo Therapeutics Inc
29/12/202303:48Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CYTHCyclo Therapeutics Inc
27/12/202322:15Business WireCyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.NASDAQ:CYTHCyclo Therapeutics Inc
18/12/202315:15Business WireCyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1NASDAQ:CYTHCyclo Therapeutics Inc
18/12/202312:02Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:CYTHCyclo Therapeutics Inc
14/12/202322:01GlobeNewswire Inc.Rafael Holdings Reports First Quarter Fiscal 2024 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
22/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTHCyclo Therapeutics Inc
21/11/202315:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CYTHCyclo Therapeutics Inc
21/11/202314:05Business WireCyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024NASDAQ:CYTHCyclo Therapeutics Inc
20/11/202314:50Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
15/11/202314:05Business WireCyclo Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
14/11/202320:41Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYTHCyclo Therapeutics Inc
07/11/202322:45Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:CYTHCyclo Therapeutics Inc
30/10/202321:01GlobeNewswire Inc.Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial ResultsNASDAQ:CYTHCyclo Therapeutics Inc
24/10/202322:43Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CYTHCyclo Therapeutics Inc
23/10/202314:05Business WireCyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 MillionNASDAQ:CYTHCyclo Therapeutics Inc
05/10/202314:05Business WireCyclo Therapeutics to Present at 8th Annual Dawson James ConferenceNASDAQ:CYTHCyclo Therapeutics Inc
21/09/202315:35GlobeNewswire Inc.Dawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceNASDAQ:CYTHCyclo Therapeutics Inc
21/09/202314:05Business WireCyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger AgreementNASDAQ:CYTHCyclo Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CYTH

La tua Cronologia

TG
A3LG55
Santander Consumer
ASX
TLSLOB
BIT
UC4KSF
Unicredit Bank
USOTC
CLTFF
Celtic (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network